Introduction: Persistent human papillomavirus (HPV) semen infection is increasingly associated with male infertility. Adjuvant HPV vaccination is suggested to reduce the time to clearance and the disease relapse in males with persistent HPV semen infection. However, only a sub-population of patients show a clinical benefit from adjuvant vaccination. Here, we aimed to address the effectiveness rate of HPV adjuvant vaccination in males with genital tract infection and the possible prognostic markers of healing. Methods: Clinical records from 379 patients with persistent seminal HPV detection, all receiving HPV adjuvant vaccination, were considered. Clinical data, including genital HPV-DNA assessment by INNO-LiPA genotyping, semen HPV-DNA analysis by FISH analysis and serum antibody titer, were collected at basal (T0) and after 6 months (T1) since the vaccination cycle ended. Results: Clearance of genital HPV-DNA was recorded in 326 (86%) patients. Serum HPV-antibody titer at T1 was the most important prognostic factor associated with HPV-DNA clearance. A serum antibody titer equal to or greater than the threshold value 1:125, obtained by ROC curve analysis, was prognostic of healing. Conclusions: Anti-HPV antibody represents a suitable marker of adequate immune response to HPV vaccination in patients with genital infection.
Introduction: Persistent humanpapillomavirus (HPV) semen infection is increasingly associated with male infertility. Adjuvant HPV vaccination is suggested to reduce the time to clearance and the disease relapse in males with persistent HPV semen infection. However, only a sub-population of patients show a clinical benefit from adjuvant vaccination. Here, we aimed to address the effectiveness rate of HPV adjuvant vaccination in males with genital tract infection and the possible prognostic markers of healing. Methods: Clinical records from 379 patients with persistent seminal HPV detection, all receiving HPV adjuvant vaccination, were considered. Clinical data, including genital HPV-DNA assessment by INNO-LiPA genotyping, semen HPV-DNA analysis by FISH analysis and serum antibody titer, were collected at basal (T0) and after 6 months (T1) since the vaccination cycle ended. Results: Clearance of genital HPV-DNA was recorded in 326 (86%) patients. Serum HPV-antibody titer at T1 was the most important prognostic factor associated with HPV-DNA clearance. A serum antibody titer equal to or greater than the threshold value 1:125, obtained by ROC curve analysis, was prognostic of healing. Conclusions: Anti-HPV antibody represents a suitable marker of adequate immune response to HPV vaccination in patients with genital infection.
Entities:
Keywords:
HPV-adjuvant vaccination; fluorescence in situ hybridization; male infertility; serum antibodies; warts
Authors: Eileen F Dunne; Carrie M Nielson; Katherine M Stone; Lauri E Markowitz; Anna R Giuliano Journal: J Infect Dis Date: 2006-09-12 Impact factor: 5.226
Authors: Carlo Foresta; Andrea Garolla; Saverio Parisi; Marco Ghezzi; Alessandro Bertoldo; Andrea Di Nisio; Luca De Toni Journal: EBioMedicine Date: 2015-10 Impact factor: 8.143
Authors: Helen C Stankiewicz Karita; Kirsten Hauge; Amalia Magaret; Constance Mao; Jeffrey Schouten; Verena Grieco; Long Fu Xi; Denise A Galloway; Margaret M Madeleine; Anna Wald Journal: JAMA Netw Open Date: 2019-04-05
Authors: María Inmaculada Rodríguez-Álvarez; Jose L Gómez-Urquiza; Husein Husein-El Ahmed; Luis Albendín-García; Juan Gómez-Salgado; Guillermo A Cañadas-De la Fuente Journal: Int J Environ Res Public Health Date: 2018-10-10 Impact factor: 3.390
Authors: Sandro La Vignera; Livia Basile; Antonio Aversa; Aldo E Calogero; Agata Grillo; Rossella Cannarella; Laura M Mongioì; Rosita A Condorelli Journal: J Clin Med Date: 2022-08-11 Impact factor: 4.964